Given the current clinical practice that the combination therapy was the standard treatment for HER2+ breast cancer, we evaluated the potential of the combination of DZD1516 with different anti-HER2 agents, especially HER2 ADCs, in animal models. This evidence concerns the gene ERBB2 and breast carcinoma.